Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant PRAME protein + AS15 adjuvant system
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant PRAME protein + AS15 adjuvant system (GSK2302032A) is an antigen-specific cancer immunotherapeutic (ASCI) developed by GSK. It consists of a recombinant form of the human PRAME (Preferentially Expressed Antigen of Melanoma) protein — a tumor-associated antigen frequently overexpressed across multiple tumor types — combined with GSK's proprietary AS15 adjuvant system. The AS15 adjuvant is a potent liposomal formulation containing CpG 7909 (a TLR9 agonist), monophosphoryl lipid A (MPL, a TLR4 agonist), and QS-21 (a saponin). Upon intramuscular administration, the vaccine is designed to stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against PRAME-overexpressing tumor cells, resulting in tumor cell lysis. The drug was primarily evaluated in Phase I and Phase II clinical trials as an adjuvant therapy in patients with resected non-small cell lung cancer (NSCLC) and metastatic melanoma. Clinical development was halted in 2016 following negative results with a similar ASCI (recMAGE-A3+AS15) in NSCLC patients.
- Other names
- PRAME immunotherapyPRAME cancer vaccine
02
Targets
TLR9 (Toll-like receptor 9)PRAME (Preferentially expressed antigen in melanoma)
Beyond the preview
Go deeper on recombinant PRAME protein + AS15 adjuvant system.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant PRAME protein + AS15 adjuvant system.